SK10552002A3 - Kombinácia a jej použitie - Google Patents

Kombinácia a jej použitie Download PDF

Info

Publication number
SK10552002A3
SK10552002A3 SK1055-2002A SK10552002A SK10552002A3 SK 10552002 A3 SK10552002 A3 SK 10552002A3 SK 10552002 A SK10552002 A SK 10552002A SK 10552002 A3 SK10552002 A3 SK 10552002A3
Authority
SK
Slovakia
Prior art keywords
mirtazapine
gepirone
combination
treatment
depression
Prior art date
Application number
SK1055-2002A
Other languages
English (en)
Slovak (sk)
Inventor
John Stuart Andrews
Wilhelmus Drinkenburg
Nicholas Matthew Ward
Original Assignee
Akzo Nobel N.V.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Akzo Nobel N.V. filed Critical Akzo Nobel N.V.
Publication of SK10552002A3 publication Critical patent/SK10552002A3/sk

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Plural Heterocyclic Compounds (AREA)
SK1055-2002A 2000-01-19 2001-01-15 Kombinácia a jej použitie SK10552002A3 (sk)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP00200189 2000-01-19
PCT/EP2001/000407 WO2001052855A2 (fr) 2000-01-19 2001-01-15 Association de medicaments pour le traitement de depressions et de troubles s'y rapportant, comprenant de la mirtazapine

Publications (1)

Publication Number Publication Date
SK10552002A3 true SK10552002A3 (sk) 2002-12-03

Family

ID=8170928

Family Applications (1)

Application Number Title Priority Date Filing Date
SK1055-2002A SK10552002A3 (sk) 2000-01-19 2001-01-15 Kombinácia a jej použitie

Country Status (21)

Country Link
US (2) US6835728B2 (fr)
EP (1) EP1251854A2 (fr)
JP (1) JP2003520237A (fr)
KR (1) KR20020068404A (fr)
CN (1) CN1223349C (fr)
AR (1) AR027240A1 (fr)
AU (1) AU780817B2 (fr)
BR (1) BR0107721A (fr)
CA (1) CA2396066A1 (fr)
CO (1) CO5261583A1 (fr)
HK (1) HK1047548A1 (fr)
HU (1) HUP0204050A3 (fr)
IL (1) IL150289A0 (fr)
MX (1) MXPA02007095A (fr)
NO (1) NO20023448L (fr)
PE (1) PE20011049A1 (fr)
PL (1) PL356605A1 (fr)
RU (1) RU2268725C2 (fr)
SK (1) SK10552002A3 (fr)
WO (1) WO2001052855A2 (fr)
ZA (1) ZA200205161B (fr)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7053092B2 (en) 2001-01-29 2006-05-30 Otsuka Pharmaceutical Co., Ltd. 5-HT1a receptor subtype agonist
AR033485A1 (es) 2001-09-25 2003-12-26 Otsuka Pharma Co Ltd Sustancia medicinal de aripiprazol de baja higroscopicidad y proceso para la preparacion de la misma
WO2006023703A2 (fr) * 2004-08-20 2006-03-02 Cypress Bioscience, Inc. Methode de traitement de troubles respiratoires lies au sommeil
WO2006055854A2 (fr) * 2004-11-17 2006-05-26 Cypress Bioscience, Inc. Methodes servant a limiter les effets secondaires d'un traitement par mirtazapine
TW200800306A (en) 2005-09-12 2008-01-01 Wyeth Corp Sustained-release formulation and uses thereof
GT200600416A (es) 2005-09-12 2007-09-20 Sales salicilato y gentisato de un compuesto de piperazina
GT200600414A (es) 2005-09-12 2007-09-20 Sal de glucuranato de compuesto de piperazine
EP1792618A1 (fr) * 2005-11-30 2007-06-06 Rainer Freynhagen R-mirtazapine pour le traitement de la douleur
AU2007253704A1 (en) * 2006-05-22 2007-11-29 Vanda Pharmaceuticals, Inc. Treatment for depressive disorders
TW200808804A (en) * 2006-05-22 2008-02-16 Organon Nv Mirtazapine for the treatment of neuropathic pain
WO2008157094A1 (fr) * 2007-06-13 2008-12-24 Cypress Bioscience, Inc. Amélioration de la tolérance à la mirtazapine et à un second principe actif par utilisation combinée de ces derniers
PL2219603T3 (pl) * 2007-11-02 2014-10-31 Acrux Dds Pty Ltd Układ transdermalnego dostarczania
US20130064770A1 (en) 2010-05-28 2013-03-14 Ge Healthcare Limited Radiolabeled compounds and methods thereof
GB201112987D0 (en) 2011-07-28 2011-09-14 Ge Healthcare Ltd Novel compound
CN108743593B (zh) * 2018-08-31 2019-03-26 程世宏 一种抗抑郁药物及其口服颗粒剂和制药用途

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NL189199C (nl) * 1975-04-05 1993-02-01 Akzo Nv Werkwijze ter bereiding van farmaceutische preparaten met werking op het centraal zenuwstelsel op basis van benz(aryl)azepinederivaten, de verkregen gevormde farmaceutische preparaten, alsmede werkwijze ter bereiding van de toe te passen benz(aryl)azepinederivaten.
US4423049A (en) * 1981-12-28 1983-12-27 Mead Johnson & Company 2-[4-[(4,4-Dialkyl-2,6-piperidinedion-1-yl)butyl]-1-piperazinyl]pyrimidines
US4771053A (en) * 1987-03-02 1988-09-13 Bristol-Myers Company Method for alleviation of primary depressive disorders
US5114976A (en) * 1989-01-06 1992-05-19 Norden Michael J Method for treating certain psychiatric disorders and certain psychiatric symptoms
US5011841B1 (en) * 1989-11-14 1994-09-06 Pfizer Treatment of depression
GB9303968D0 (en) * 1993-02-26 1993-04-14 Wyeth John & Brother Ltd 5-ht1a ligands
GB9603136D0 (en) * 1996-02-15 1996-04-17 Merck Sharp & Dohme Therapeutic agents
IL121076A (en) * 1996-06-19 2000-10-31 Akzo Nobel Nv Pharmaceutical combinations comprising mirtazapine and one or more selective serotonin reuptake inhibitors
ZA982368B (en) * 1997-03-27 1998-09-23 Akzo Nobel Nv New therapeutic combinations
TW587938B (en) 1997-03-27 2004-05-21 Akzo Nobel Nv Pharmaceutical composition for the treatment and/or prophylaxis of psychotic disorder

Also Published As

Publication number Publication date
WO2001052855A2 (fr) 2001-07-26
PE20011049A1 (es) 2001-10-18
ZA200205161B (en) 2003-09-29
MXPA02007095A (es) 2003-04-14
RU2002122084A (ru) 2004-03-10
AU780817B2 (en) 2005-04-21
HUP0204050A2 (hu) 2003-03-28
PL356605A1 (en) 2004-06-28
HUP0204050A3 (en) 2004-09-28
HK1047548A1 (zh) 2003-02-28
AU2516201A (en) 2001-07-31
CN1395486A (zh) 2003-02-05
AR027240A1 (es) 2003-03-19
NO20023448D0 (no) 2002-07-18
IL150289A0 (en) 2002-12-01
WO2001052855A8 (fr) 2002-12-27
US6835728B2 (en) 2004-12-28
BR0107721A (pt) 2002-10-01
US20050090488A1 (en) 2005-04-28
CA2396066A1 (fr) 2001-07-26
NO20023448L (no) 2002-09-17
US20030105083A1 (en) 2003-06-05
WO2001052855A3 (fr) 2002-01-10
JP2003520237A (ja) 2003-07-02
CN1223349C (zh) 2005-10-19
RU2268725C2 (ru) 2006-01-27
CO5261583A1 (es) 2003-03-31
EP1251854A2 (fr) 2002-10-30
KR20020068404A (ko) 2002-08-27

Similar Documents

Publication Publication Date Title
JP4249415B2 (ja) Ｃｎｓ疾患の治療のためのピロリジンアセトアミド誘導体単体又は組み合わせ物
US20050096311A1 (en) Compositions and methods for treatment of nervous system disorders
EP1994932A1 (fr) Utilisation de N-desmethylclozapine pour traiter les psychoses humaines
US20080214592A1 (en) Methods of treating anxiety disorders
US20060122127A1 (en) Methods for reducing the side effects associated with mirtzapine treatment
SK10552002A3 (sk) Kombinácia a jej použitie
EP3655036B1 (fr) Compositions pour le traitement de troubles liès au stress
CA2500662A1 (fr) Escalade posologique et dose quotidienne fractionnee d'antidepresseurs pour traiter des troubles neurologiques
US9732059B2 (en) Methods of use of cyclic amide derivatives to treat schizophrenia
US20080004284A1 (en) Method for treating fibromyalgia syndrome and related conditions
KR100425045B1 (ko) 약물중독의치료를위한멜라토닌함유약학적조성물
WO1993021917A1 (fr) Inhibiteurs de recaptage de dopamine et noradrenergique utilises dans le traitement de la schizophrenie
US20180155318A1 (en) Methods of use of cyclic amide derivatives to treat schizophrenia
KR20100038120A (ko) 신경퇴행성 장애의 치료를 위한 신규한 네라멕산 조합물
EP4417258A2 (fr) Schémas posologiques pour l'utilisation de ly3154207 dans le traitement de troubles du système nerveux central dopaminergiques
SK284521B6 (sk) Použitie melatonínu na prípravu farmaceutického prostriedku
US6979698B1 (en) Method of treating cognitive deficits in learning and memory
Goldberg Sustained yawning as a side effect of imipramine
CN101028265A (zh) 一种改善睡眠调整睡醒节律的黑白药物组合物
WO2005097138A2 (fr) Combinaisons comprenant de l'oxcarbazepine pour le traitement de troubles affectifs
CN1931153A (zh) 用于治疗抑郁症及相关病症的包括文拉法辛的药物组合物
Lahmeyer Pharmacology of sleep
Lindsey Effects of monoamine transporter blockers on cocaine self-administration: Relation to dopamine transporter occupancy measured by PET in rhesus monkeys. An investigation of substitute agonist therapeutic strategies for cocaine addiction
WO2002016347A1 (fr) Metabolite actif de gepirone
MXPA97005856A (en) Use of melatonine in the manufacture of unmedicament to deal with addiction to dro

Legal Events

Date Code Title Description
FC9A Refused patent application